Exchange: NASDAQ·Updated 04:39 PM EST

PRQR News

News
all
press releases
HC Wainwright Has Negative Opinion of PRQR FY2026 Earnings
ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright cut their FY2026 earnings per share estimates for ProQR Therapeutics in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst A. Ghosh now anticipates that the biophar...
MarketBeat
HC Wainwright Has Negative Opinion of PRQR FY2026 Earnings
ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright cut their FY2026 earnings per share estimates for ProQR Therapeutics in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst A. Ghosh now anticipates that the biophar...
MarketBeat
More News
Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.read more...
Benzinga
Kamada (KMDA) delivered earnings and revenue surprises of -40.02% and -2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Syndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 1,261,281 shares, a decrease of 24.4% from the March 31st total of 1,667,465 shares. Currently, 1.3% of the shares...
MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have...
MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above Fifty Day Moving Average - Should You Sell...
MarketBeat
Chardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday...
MarketBeat

Advertisement|Remove ads.